

## Special Issue

# Emerging Pharmaceutical Therapeutics for Neglected Tropical Diseases

### Message from the Guest Editors

In the recent past, several new candidates were identified for neglected tropical diseases (NTDs). While the first drugs were registered, e.g., fexinidazole for sleeping sickness or miltefosin and paromomycin combination for leishmaniasis in Africa, more drug candidates are in development (e.g., phase 2b/3 studies for leishmaniasis, Chagas disease or mycetoma). However, for some NTDs, the pipeline of new drug candidates is not well equipped, and only a few candidates are within phase 1 or 2 clinical trials (e.g., for onchocerciasis). In the present Special Issue, we ask authors to submit original research and review articles that relate to drug candidates for NTDs with special emphasis on their formulation, dosage form, drug delivery and pharmacokinetics, etc., as is the scope of the journal.

---

### Guest Editors

Prof. Dr. Achim Hoerauf

Institute of Medical Microbiology, Immunology and Parasitology,  
University Hospital Bonn, Bonn, Germany

Prof. Dr. Marc Hübner

Institute of Medical Microbiology, Immunology and Parasitology,  
University Hospital Bonn, Bonn, Germany

---

### Deadline for manuscript submissions

closed (30 April 2024)



## Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/174250](https://mdpi.com/si/174250)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).